Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, parallel-group, 6 week treatment, multi-center, phase III study to investigate the efficacy and safety of 100 microg and 200 microg twice daily of budesonide turbuhaler and 50 microg and 100 microg twice daily of fluticasone Diskus in Japanese children with bronchial asthma aged 5-15

Trial Profile

A randomized, open-label, parallel-group, 6 week treatment, multi-center, phase III study to investigate the efficacy and safety of 100 microg and 200 microg twice daily of budesonide turbuhaler and 50 microg and 100 microg twice daily of fluticasone Diskus in Japanese children with bronchial asthma aged 5-15

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 16 May 2010 Results were presented at the 106th International Conference of the American Thoracic Society.
  • 18 Dec 2007 Status change from in progress to completed.
  • 10 Aug 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top